Bacteriophage Therapy Market Forecasts to 2030 - Global Analysis By Product, Type, Targeted Bacteria, Disease Indication, Route of Administration, Distribution Channel, Application, End User and By Geography

According to Stratistics MRC, the Global Bacteriophage Therapy Market is accounted for $46.59 million in 2023 and is expected to reach $80.90 million by 2030 growing at a CAGR of 8.2% during the forecast period. Bacteriophages are viruses that only attack and kill bacteria. They are among the most prevalent biological organisms capable of battling and eliminating bacteria with multiple drug resistances. Phages can eliminate the bacteria causing an infection when all other antibiotics have failed to treat it, enabling medical professionals to save a life. Additionally, bacteriophages are being investigated as an alternative to antibiotics. In this therapy, viruses are used to inject bacteria with their genetic material so that the bacteria can use the machinery of their hosts to grow.

According to the Centers for Disease Control and Prevention (CDC), antibiotic-resistant bacterial infections affect approximately 33 000 people in Europe each year. Antibiotic resistance is predicted to increase globally, creating considerable demand for bacteriophages.

Market Dynamics:

Driver:

Increasing antibiotic resistance

The overuse and abuse of antibiotics in both human medicine and agriculture have serious consequences, including the rise in antibiotic resistance. Antibiotic-resistant superbugs have emerged as a result of this worrying trend, necessitating the urgent need for alternative therapies like bacteriophage therapy. Moreover, bacteriophages are naturally occurring viruses that target and destroy bacteria, making them a promising weapon against these pathogens that are drug-resistant. Researchers are investigating how to effectively target and get rid of these tough bacterial strains using phage cocktails and specially created phages.

Restraint:

Insufficient clinical data and regulatory obstacles

It is difficult to persuade regulatory agencies of the safety and effectiveness of bacteriophage therapy because there aren't many large-scale, randomized controlled trials that can provide sufficient clinical evidence. However, it may take longer to get a product approved for the market and cost more money because of the strict regulatory environment for new therapies and the requirement for extensive clinical data. While overcoming these challenges, developers must also address issues with the consistency and quality of phage preparations used in clinical trials.

Opportunity:

Investments in research and development

Innovation in bacteriophage therapy is accelerating as a result of the surge in R&D spending. Phage engineering, the creation of phage libraries, and the combination of phage therapy with other therapeutic modalities like immunotherapies or antibiotics are all topics of active research. Moreover, this dynamic environment encourages a deeper comprehension of phage biology and its clinical applications, in addition to diversifying the therapeutic toolbox.

Threat:

Regulatory issues and a lack of robust clinical data

Lack of large-scale, top-notch clinical data is one of the biggest threats to the bacteriophage therapy market. Because there have been relatively few clinical trials for bacteriophage therapy, regulatory agencies may delay approvals and raise development costs. Furthermore, regulatory agencies need strong clinical evidence to approve new therapies. It can be challenging and time-consuming for developers to navigate the regulatory environment for novel therapies.

COVID-19 Impact:

The bacteriophage therapy market has been affected in different ways by the COVID-19 pandemic. Although bacteriophages and other alternative therapies have received more attention due to the increased focus on infectious diseases and antibiotic resistance, the pandemic has also focused more resources, attention, and research efforts on COVID-19. Due to supply chain issues, bacteriophage therapy clinical trials and research were delayed, and some production interruptions happened. Despite this, the pandemic brought attention to the need for a wider range of treatment options, which may hasten the adoption of bacteriophage therapy in the post-pandemic era, particularly for persistent bacterial threats in healthcare settings and antibiotic-resistant infections.

The Urinary Tract Infections segment is expected to be the largest during the forecast period

In the market for bacteriophage therapy, the urinary tract infections (UTIs) segment commands the largest share. Each year, millions of people experience UTIs, which are among the most prevalent bacterial infections. Moreover, bacteriophage therapy has become a promising alternative due to the rise in antibiotic-resistant strains that cause UTIs. It is a compelling option for both simple and complex UTIs due to its effectiveness in targeting particular uropathogenic bacteria. Further boosting the market potential for bacteriophage-based treatments in this market are the recurrent nature of UTIs and the limitations of antibiotics in preventing relapses.

The Antimicrobial Drug Discovery segment is expected to have the highest CAGR during the forecast period

In the market for bacteriophage therapy, antimicrobial drug discovery is growing at the highest CAGR. There has been an increase in funding and research into finding new antimicrobial agents as a result of the growing concern about antibiotic resistance around the world. The ability of bacteriophages to target and destroy bacteria that are resistant to antibiotics has attracted a lot of interest in drug discovery efforts. Furthermore, the ongoing investigation of bacteriophages potential for locating and creating novel antimicrobial remedies-solutions that are urgently required to address the mounting problem of drug-resistant infections-is the primary driver of this market's rapid growth.

Region with largest share:

The largest market share for bacteriophage therapy is anticipated to be in the North American region. A number of elements, such as a strong healthcare infrastructure, a high incidence of infections caused by bacteria resistant to antibiotics, significant investments in research and development, and a supportive regulatory environment, can be credited for this dominance. The region's thriving biotechnology and pharmaceutical sectors, along with the growing use of bacteriophage therapy in clinical settings, place North America as a market leader. Additionally, bacteriophage therapy has expanded more quickly in North America thanks to partnerships between academic institutions, pharmaceutical companies, and governmental organizations, where it now accounts for the largest market share.

Region with highest CAGR:

In the global market for bacteriophage therapy, Asia-Pacific is growing at the highest CAGR. This rapid expansion is a result of a number of factors, including the heavy prevalence of infections that are resistant to antibiotics, the expanding healthcare industry, and growing public awareness of the potential advantages of bacteriophage therapy. With a focus on creating efficient production techniques and extending clinical applications, the Asia-Pacific region is seeing significant investments in research and development. Furthermore, collaborations between local academic institutions, pharmaceutical firms from abroad, and regional biotechnology companies are promoting innovation and expanding the market.

Key players in the market:

Some of the key players in Bacteriophage Therapy market include: InnoPhage Ltd, Eliava Biopreparations Ltd., Adaptive Phage Therapeutics, Inc, Nextbiotics, Armata Pharmaceuticals Inc., Enbiotix Inc., Eligo Bioscience SA, BiomX Ltd., Phagomed Biopharma GmbH, Intodeworld Inc., Phi Therapeutics, ContraFect Corporation, Locus Biosciences Inc., Intralytix Inc., PhagePro Inc., Pherecydes Pharma and TechnoPhage SA.

Key Developments:

In May 2023, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center. Researchers at the IPTC have discovered several phages that have exceptionally broad coverage against antibiotic resistant bacteria.

In January 2023, Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc, Armata's largest shareholder.

In July 2022, Micro biome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD). BiomX Ltd. The agreement, the second one between the two firms, uses BiomX's XMarker micro biome-based biomarker discovery platform to aid in identifying IBD-linked pathogenic bacterium. Additional agreement terms see BiomX receive research payments with Boehringer able to negotiate an exclusive right to biomarkers discovered under the collaboration.

Products Covered:

• Phage Probiotics
• Phage Therapeutic
• Other Products

Types Covered:

• Lytic
• Lysogenic
• Other Types

Targeted Bacterias Covered:

• Escherichia Coli
• Staphylococcus Aureus
• Streptococcus
• Pseudomonas Aeruginosa
• Salmonella
• Other Targeted Bacterias

Disease Indications Covered:

• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications

Route of Administrations Covered:

• Oral
• Topical
• Parenteral

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Applications Covered:

• Skin Infection Treatment
• Gastroenterology
• Wound Prophylaxis
• Respiratory Infections Treatment
• Urogenital Infection Treatment
• Diagnostic
• Antimicrobial Drug Discovery
• Veterinary Medicines
• Other Applications

End Users Covered:

• Hospitals & Clinics
• Academic Research Organizations & Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances